BRPI0516727A - métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença - Google Patents
métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doençaInfo
- Publication number
- BRPI0516727A BRPI0516727A BRPI0516727-2A BRPI0516727A BRPI0516727A BR PI0516727 A BRPI0516727 A BR PI0516727A BR PI0516727 A BRPI0516727 A BR PI0516727A BR PI0516727 A BRPI0516727 A BR PI0516727A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- methods
- inhibiting
- disease
- growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61528404P | 2004-10-01 | 2004-10-01 | |
PCT/US2005/035477 WO2006039644A2 (en) | 2004-10-01 | 2005-09-30 | Methods of treating cd30 positive lymphomas |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0516727A true BRPI0516727A (pt) | 2008-09-16 |
Family
ID=35929979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0516727-2A BRPI0516727A (pt) | 2004-10-01 | 2005-09-30 | métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença |
Country Status (13)
Country | Link |
---|---|
US (1) | US7790160B2 (ko) |
EP (1) | EP1802345A2 (ko) |
JP (1) | JP2008514730A (ko) |
KR (1) | KR20070083899A (ko) |
CN (1) | CN101056655A (ko) |
AU (1) | AU2005292227A1 (ko) |
BR (1) | BRPI0516727A (ko) |
CA (1) | CA2582016A1 (ko) |
IL (1) | IL182260A0 (ko) |
MX (1) | MX2007003533A (ko) |
NO (1) | NO20071714L (ko) |
WO (1) | WO2006039644A2 (ko) |
ZA (1) | ZA200703154B (ko) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1638800A (zh) * | 2002-01-09 | 2005-07-13 | 米德列斯公司 | 抗cd30的人类单克隆抗体 |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
MX2007003533A (es) | 2004-10-01 | 2007-05-23 | Medarex Inc | Metodos de tratar linfomas cd30 positivas. |
JP2008530244A (ja) * | 2005-02-18 | 2008-08-07 | メダレックス, インク. | フコシル残基を欠くcd30に対するモノクローナル抗体 |
US20090214544A1 (en) * | 2005-04-25 | 2009-08-27 | Medarex | Method of treating cd30 positive lymphomas |
EP1976883B1 (en) * | 2006-01-17 | 2012-10-03 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
CA2683643C (en) * | 2007-04-10 | 2015-11-24 | Martin G. Pomper | Imaging and therapy of virus-associated tumors |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EA201890869A3 (ru) | 2010-06-03 | 2019-03-29 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) |
EP2812702B1 (en) | 2012-02-10 | 2019-04-17 | Seattle Genetics, Inc. | Diagnosis and management of CD30-expressing cancers |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
EP3508502B1 (en) | 2013-09-20 | 2023-04-26 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
EA201690746A1 (ru) * | 2013-10-25 | 2016-12-30 | Фармасайкликс Элэлси | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии |
US10335494B2 (en) * | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
EP3116909B1 (en) * | 2014-03-14 | 2019-11-13 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
CA2954694A1 (en) * | 2014-07-11 | 2016-01-14 | Expression Pathology, Inc. | Srm/mrm assay for the tumor necrosis factor receptor superfamily member 8 (cd30) protein |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
CA3032011A1 (en) * | 2016-08-04 | 2018-02-08 | Millennium Pharmaceuticals, Inc. | Combination of proteasome inhibitors and anti-cd30 antibodies |
CN106854245A (zh) * | 2016-12-28 | 2017-06-16 | 无锡傲锐东源生物科技有限公司 | 抗cd30蛋白单克隆抗体及其用途 |
AU2018277824A1 (en) | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Treatment of LAG-3 positive tumors |
MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
WO2019148410A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
JP2024508509A (ja) | 2021-03-01 | 2024-02-27 | ナントバイオ,インコーポレイテッド | 抗cd30モノクローナル抗体及びキメラ抗原受容体 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6909191A (en) | 1989-11-20 | 1991-06-13 | Parker, David L. | Improved cd-30 antibodies and fragments thereof |
US5165923A (en) | 1989-11-20 | 1992-11-24 | Imperial Cancer Research Technology | Methods and compositions for the treatment of hodgkin's disease |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE4200043A1 (de) | 1991-11-11 | 1993-05-13 | Stein Harald Prof Dr | Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren |
WO1993024135A1 (en) | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
AU4953693A (en) | 1992-08-25 | 1994-03-15 | Medac Gesellschaft Fur Klinische Spezialpraparate Mbh | Antibody/radioisotope conjugate for tumor diagnosis and/or therapy |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
DE69605181T3 (de) | 1995-01-18 | 2006-08-24 | Roche Diagnostics Gmbh | Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern |
DE19543039C1 (de) | 1995-11-08 | 1996-11-21 | Medac Klinische Spezialpraep | Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30 |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
WO1999040187A1 (de) | 1998-02-06 | 1999-08-12 | Hinrich Abken | Nukleinsäuren zur modulation zellulärer aktivierung |
DE19937264A1 (de) | 1999-08-06 | 2001-02-15 | Deutsches Krebsforsch | F¶v¶-Antikörper-Konstrukte |
US6652854B2 (en) | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
AU2001285286A1 (en) | 2000-08-29 | 2002-03-13 | Noveon Ip Holdings Corp. | Hydrogels containing substances |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
AU2002337935B2 (en) * | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
CN1638800A (zh) * | 2002-01-09 | 2005-07-13 | 米德列斯公司 | 抗cd30的人类单克隆抗体 |
WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
FR2844513B1 (fr) | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
MX2007003533A (es) | 2004-10-01 | 2007-05-23 | Medarex Inc | Metodos de tratar linfomas cd30 positivas. |
JP2008530244A (ja) | 2005-02-18 | 2008-08-07 | メダレックス, インク. | フコシル残基を欠くcd30に対するモノクローナル抗体 |
-
2005
- 2005-09-30 MX MX2007003533A patent/MX2007003533A/es not_active Application Discontinuation
- 2005-09-30 CA CA002582016A patent/CA2582016A1/en not_active Abandoned
- 2005-09-30 ZA ZA200703154A patent/ZA200703154B/xx unknown
- 2005-09-30 KR KR1020077009968A patent/KR20070083899A/ko not_active Application Discontinuation
- 2005-09-30 AU AU2005292227A patent/AU2005292227A1/en not_active Abandoned
- 2005-09-30 EP EP05816220A patent/EP1802345A2/en not_active Withdrawn
- 2005-09-30 CN CNA2005800383614A patent/CN101056655A/zh active Pending
- 2005-09-30 WO PCT/US2005/035477 patent/WO2006039644A2/en active Application Filing
- 2005-09-30 JP JP2007534859A patent/JP2008514730A/ja active Pending
- 2005-09-30 US US11/241,154 patent/US7790160B2/en not_active Expired - Fee Related
- 2005-09-30 BR BRPI0516727-2A patent/BRPI0516727A/pt not_active IP Right Cessation
-
2007
- 2007-03-28 IL IL182260A patent/IL182260A0/en unknown
- 2007-03-30 NO NO20071714A patent/NO20071714L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1802345A2 (en) | 2007-07-04 |
KR20070083899A (ko) | 2007-08-24 |
AU2005292227A1 (en) | 2006-04-13 |
IL182260A0 (en) | 2007-07-24 |
CA2582016A1 (en) | 2006-04-13 |
US20060177442A1 (en) | 2006-08-10 |
ZA200703154B (en) | 2008-09-25 |
WO2006039644A2 (en) | 2006-04-13 |
JP2008514730A (ja) | 2008-05-08 |
WO2006039644A3 (en) | 2006-08-10 |
MX2007003533A (es) | 2007-05-23 |
CN101056655A (zh) | 2007-10-17 |
NO20071714L (no) | 2007-06-28 |
US7790160B2 (en) | 2010-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0516727A (pt) | métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença | |
NL301145I2 (nl) | Tirbanibulin | |
CY1122522T1 (el) | Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος | |
CY1120961T1 (el) | Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος | |
MX2009010284A (es) | Inhibidores de la tirosina-cinasa de bruton. | |
WO2010031056A3 (en) | Methods and compositions for modulating ire1, src, and abl activity | |
GT200600407A (es) | Compuestos ppar activos | |
TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
TW200716624A (en) | Compounds for modulating TRPV3 function | |
MXPA05013977A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
SG166813A1 (en) | 5-lipoxygenase-activating protein (flap) inhibitors | |
CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
NO20075865L (no) | Innelukket behandlingskjemikalie og fremgangsmate for forsinket frigivelse av samme | |
SG165387A1 (en) | 5-lipoxygenase-activating protein (flap) inhibitors | |
EA200200105A1 (ru) | СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ; | |
TW200714283A (en) | Method and composition for treating peripheral vascular diseases | |
BR0312785A (pt) | Tratamento de desordens relacionadas a tnf(alfa) | |
BRPI0517091B8 (pt) | composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida | |
MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
EA200801942A1 (ru) | Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон | |
BRPI0607351A2 (pt) | métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20 | |
EP1952613A4 (en) | MEDIATOR, SOURCE AND METHOD FOR THE COMMON USE OF CONTENTS | |
NO20070351L (no) | Materialer og fremgangsmater for forbedring av skalldyrhelse, -immunitet og -vekst | |
WO2009023846A3 (en) | Methods for heat shock protein dependent cancer treatment | |
MX2009003022A (es) | Composiciones y metodos para tratar picaduras de medusa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |